Company Overview and News

42
Trade of the Day: CME Group Inc (CME)

2018-06-15 investorplace
To receive further updates on this CME Group Inc (NASDAQ:CME) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
NDAQ 7018 CME

36
CME / CME Group, Inc. 424B5 (Prospectus)

2018-06-15 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-208334 CALCULATION OF REGISTRATION FEE
CME

40
PFM: You May Want To Sell

2018-06-15 seekingalpha
With the Fed raising its key interest rate, it is a reminder we have to be very selective with what dividend funds we choose.
VIG 7018 CME

107
The EU Is Emerging as the New Sheriff for Global Financial Markets - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB 7018 CME MSFT

60
CME Group (CME) Prices $1.2 Billion Senior Unsecured Notes

2018-06-15 zacks
CME Group (CME - Free Report) recently announced the pricing of $1.2 billion senior notes. The notes will be issued in two tranches, 3.75% $500 million senior unsecured notes due 2028 and 4.15% $700 million senior unsecured notes due 2048. The company intends to deploy the proceeds from this offering along with cash in hand to finance the cash consideration of NEX Group plc by CME Group and CME London Limited.
SPG.PRJ 7018 CME CNA SPG NEXGY AB

40
Crypto coins surge after US regulator says they aren’t subject to securities rules

2018-06-15 scmp
Crypto enthusiasts have long worried that the SEC would crack down on Ether, which was originally offered in 2014 by the Ethereum Foundation, a Swiss nonprofit.
7018 CME

40
Bitcoin will be impossible to reflate into a bubble again - MarketWatch

2018-06-14 marketwatch
Also, with the Federal Reserve’s quantitative-tightening operations, there’s the potential for a much bigger dollar spike
7018 CME

35
CME / CME Group, Inc. FWP

2018-06-14 sec.gov
FWP Filed Pursuant to Rule 433 Free Writing Prospectus Registration Statement No. 333-208334 Pricing Term Sheet
CME

40
Novogratz Firm Makes $15 Million Investment in Crypto Startup - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7018 CME

40
Crypto Coins Surge as SEC Spares Ether From Securities Rules - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7018 CME

40
Fed lifts rates as inflation picks up, drops crisis-era guidance

2018-06-14 bworldonline
WASHINGTON — The Federal Reserve raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the US central bank’s shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

40
Multimedia Weekly Digest: FOMC Hikes Again

2018-06-14 seekingalpha
Every week, we compile some of the best podcasts and videos our authors have to offer.
7018 CME

40
Fed lifts interest rates amid stronger inflation, drops crisis-era guidance

2018-06-14 thehindubusinessline
The Federal Reserve had raised interest rates on Wednesday, a move that was widely expected but still marked a milestone in the US central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
OBZIY OBEROIRLTY 7018 CME 533273

35
CME / CME Group, Inc. 424B5 (Prospectus)

2018-06-14 sec.gov
424B5 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
CME

40
Fed lifts rates amid stronger inflation, drops crisis-era guidance

2018-06-13 malaymail
WASHINGTON, June 14 — The Federal Reserve raised interest rates on yesterday, a move that was widely expected but still marked a milestone in the US central bank's shift from policies used to battle the 2007-2009 financial crisis and recession.
7018 CME

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to CME / CME Group, Inc. on message board site Silicon Investor.

Porkbelly futures u0026 political ramifications of Pork Tarrifs VOISEY BAYu0027S FIND - A NEW DISCOVERY
Cmec Acme Packet (APKT)
Colorado MEDtech, CMED CELTIC MINERALS LTD A COMPANY TO WATCH SHORT AND LONG TERM
Acme United Corp (ACU) Celtic Minerals
Commercial concepts CMEC American Realty Trust (ARB)-TCI, IOT, CMETS
CUSIP: 12572Q105